Want to see IN:VIKASLIFE full AI Analyst Report?
Top Page
Vikas Lifecare Limited
(VIKASLIFE)
Select Model
Select Model
Rating:55Neutral
Price Target:
₹1.50
▲(13.64% Upside)
Action:Reiterated
Date:08/27/26
The score is driven primarily by improving financial flexibility (modest leverage) and a notable recent cash-flow inflection, offset by weak and volatile operating profitability. Technicals remain mixed with a short-term rebound but longer-term downtrend signals, and valuation is constrained by a negative P/E and no provided dividend yield.
Positive Factors
Strong Revenue Scale-Up
The significant multi-year revenue increase indicates broader commercial scale and higher transaction volumes. For a distribution business, sustained expansion can improve supplier access, customer reach, logistics utilization, and operating leverage if margins stabilize.
Negative Factors
Weak Operating Profitability
Operating losses and thin gross margins weaken earnings quality and leave limited protection against procurement, logistics, or commodity-price pressures. Without durable margin improvement, higher revenue may not translate into stronger shareholder returns.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Revenue Scale-Up
The significant multi-year revenue increase indicates broader commercial scale and higher transaction volumes. For a distribution business, sustained expansion can improve supplier access, customer reach, logistics utilization, and operating leverage if margins stabilize.
Read all positive factors
Vikas Lifecare Limited (VIKASLIFE) vs. iShares MSCI India ETF (INDA)
Market Cap
₹2.28B
Dividend YieldN/A
Average Volume (3M)556.56K
Price to Earnings (P/E)―
Beta (1Y)1.18
Revenue Growth4.03%
EPS Growth-1217.25%
CountryIN
Employees36
SectorGeneral
Sector StrengthN/A
IndustryChemicals - Specialty
Share Statistics
EPS (TTM)-0.72
Shares Outstanding1,857,668,600
10 Day Avg. Volume434,922
30 Day Avg. Volume556,562
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)0.16
Price to Sales (P/S)0.18
P/FCF Ratio0.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Vikas Lifecare Limited Business Overview & Revenue Model
Company Description
Established in 1995 and headquartered in New Delhi, India, Vikas Lifecare Limited (which operated as Vikas Multicorp Limited until its name change in April 2021) is a multifaceted company with diverse operations. Its business is organized into Rea...
How the Company Makes Money
The company primarily makes money by buying industrial raw materials (notably polymers and plastic-related inputs and other allied materials) from producers/import channels and selling them to industrial customers through a distribution/trading mo...
Vikas Lifecare Limited Financial Statement Overview
Summary
Income Statement
42
Neutral
Balance Sheet
68
Positive
Cash Flow
74
Positive
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 4.99B | 4.80B | 4.46B | 4.76B | 3.01B |
| Gross Profit | 55.92M | 38.79M | 262.04M | 243.20M | 101.59M |
| EBITDA | 195.84M | 43.56M | 240.93M | -160.98M | 427.24M |
| Net Income | 184.09M | -106.14M | 140.29M | -152.99M | 286.99M |
Balance Sheet | |||||
| Total Assets | 7.60B | 7.29B | 5.55B | 4.55B | 3.21B |
| Cash, Cash Equivalents and Short-Term Investments | 10.80M | 431.74M | 159.36M | 113.13M | 77.05M |
| Total Debt | 1.05B | 767.00M | 344.90M | 304.07M | 230.77M |
| Total Liabilities | 2.09B | 1.96B | 762.67M | 1.21B | 1.21B |
| Stockholders Equity | 5.51B | 5.32B | 4.77B | 3.31B | 1.99B |
Cash Flow | |||||
| Free Cash Flow | 4.35B | -2.36B | -577.20M | -1.28B | -281.03M |
| Operating Cash Flow | 4.36B | -2.24B | -417.48M | -1.10B | -148.84M |
| Investing Cash Flow | -4.67B | 1.03B | -906.01M | -366.38M | -385.14M |
| Financing Cash Flow | 261.45M | 1.12B | 1.37B | 1.51B | 590.87M |
Vikas Lifecare Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | ₹13.70B | 16.47 | ― | 0.89% | 40.77% | 54.07% | |
61 Neutral | ₹2.90B | 14.07 | ― | 0.65% | -2.95% | 18.30% | |
57 Neutral | ₹24.78B | 16.46 | ― | 0.11% | 19.47% | 11.49% | |
56 Neutral | ₹4.33B | 23.45 | ― | 0.19% | 25.22% | 20.38% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
55 Neutral | ₹2.28B | -1.71 | ― | ― | 4.03% | -1217.25% | |
48 Neutral | ₹17.96B | 336.27 | ― | 0.09% | 13.55% | -77.69% |
* General Sector Average
IN:VIKASLIFE
Vikas Lifecare Limited
1.23
-1.00
-44.84%
IN:AARTISURF
Aarti Surfactants Ltd.
511.40
21.75
4.44%
IN:AVTNPL
AVT Natural Products Limited
89.96
16.50
22.45%
IN:DYNPRO
Dynemic Products Limited
233.20
-131.52
-36.06%
IN:OAL
Oriental Aromatics Ltd.
533.75
198.19
59.06%
IN:ROSSARI
Rossari Biotech Ltd
447.40
-196.98
-30.57%
Vikas Lifecare Limited Corporate Events
Vikas Lifecare Says Promoter’s ED Custody Has No Material Impact on Operations
Jul 15, 2026
Vikas Lifecare Limited has disclosed that one of its promoters, Vikas Garg, has been taken into custody by India’s Directorate of Enforcement under the Prevention of Money Laundering Act in connection with an ongoing probe into transactions ...
Vikas Lifecare Board Clears FY26 Results Amid Auditor’s Qualified Opinion
Jun 24, 2026
Vikas Lifecare Limited’s board has approved the standalone and consolidated audited financial results for the quarter and financial year ended March 31, 2026, at a meeting held on June 24, 2026. The board meeting, which ran from early evenin...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.